deliv anoth stellar quarter thank mako
updat forecast estim oct
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim oct
price data oct
rate updat oct
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
remain top-tier competitor sever attract medic
market includ orthoped implant medic surgic
equip neurovascular product enjoy long record
innov key market anticip pattern
continu allow wide-moat compani earn attract
contrast rival zimmer biomet aim diversifi
eas relianc larg joint implant benefit
strategi becam clear great recess push
orthoped market slow-growth mode demonstr
histor recession-resist busi inde vulner
mani uneasi patient defer elect procedur stryker
also rel less vulner increas price pressur
hip knee alway like presenc
medical-surg equip area offer measur
stabil diminish impact period econom
downturn vari product line also mean
opportun engin meaning innov critic
gain price advantag continu pursu
strategi augment intern innov acquisit
bone innov mako fit firm
larger goal partner close hospit custom
across multipl devic equip categori
see opportun optim synergist
innov across diverg busi segment
extens breadth product nonetheless serv stryker
well hospit custom seek consolid supplier order
take advantag volum discount moreov stryker
manag demonstr acut understand new
opportun med-tech competitor arisen thank
shift toward value-bas reimburs squeez
provid anticip continu make strateg
acquisit technolog product aim avoid
complic cut cost
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
design manufactur market array medic equip
instrument consum suppli implant devic product
portfolio includ hip knee replac endoscopi system oper
room equip embol coil spinal devic remain one
three largest competitor reconstruct orthoped implant
hold leadership posit oper room equip approxim
total revenu current come outsid unit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
deliv anoth stellar quarter thank mako
neurotechnolog rais fve oct
stryker third-quart result demonstr well
firm meld smart strategi top-notch
execut year-to-d perform
consist track along expect
alter underli assumpt modestli
rais fair valu estim reflect cash flow realiz
sinc last updat continu fan stryker
wide moat though share consist trade
intrins valu past two half year
weve seen nine quarter grown
knee implant faster market primarili fuel
mako robot third quarter saw knee
rise johnson johnson knee fell
continu steadili place robot train
surgeon firm shi instal
robot notabl util rate grown year
year perhap intrigu hint one
publish prospect studi suggest compar
significantli decreas pain faster recoveri earli
discharg hospit anoth studi found mako
knee patient typic cost approxim less
treat less like use skill nurs follow
surgeri readmiss one third lower
non-mako patient preliminari indic
leav us optimist clinic econom
benefit mako favor data share
major orthoped confer march plan revisit
assumpt long-term mako placement
also continu see strength neurotechnolog
segment firm abl benefit
beefed-up product portfolio coil cathet well
grow adopt stent retriev ischem stroke
expect see low double-digit growth
final think stryker plan acquisit
savvi decis whole fan spine
market domin cater primari
patient degen spinal condit weve long
held clinic underpin mani commonli
perform spinal procedur shaki best
high-qual random control prospect
studi compar outcom procedur
studi exist suggest conserv
measur physic therapi may work well
invas spinal surgeri
come
howev squar aim complic spinal
market primarili compos moder sever
scoliosi patient pediatr adolesc adult
spine trauma mix clinic valu surgic
treatment type patient clear
significantli higher seen among
degen spinal patient thank foundat
clinic benefit reimburs well-establish
point addit immateri
financi standpoint howev view acquisit
anoth exampl manag team acut
discern
modestli increas fair valu estim
per share account cash flow realiz sinc
last updat continu hold rel optimist
project growth knee trauma extrem
medic product neurovascular next five
year becom confid oper
chang firm implement lead sustain
gain effici sale perform addit
think could take time zimmer biomet fulli
address regulatori production/inventori issu
well difficult task meld cultur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
year double-digit growth neurotech off-set
basi averag volatil cash flow
divers product portfolio rate uncertainti
bullish scenario assum reconstruct
grow faster rate aid growth
trauma extrem well growth
top-lin sale add averag annual growth
case reform sale market structur
anticip boost spend
moder initi expect result
improv adjust oper margin
case peg fair valu per share
valu bear-cas scenario reflect
mid-single-digit growth larg joint
rel matur technolog also assum
edg trauma extrem
competitor success launch product
medical-surg segment grow temper
rate physio-control integr
weaker-than-expect spine sale off-set growth
neurotech project oper margin peak
manufactur cost fall slightli partial
off-set higher cost
dug wide econom moat thank
competit advantag across key busi think
signific switch cost surgeon
still influenti decision-mak implant brand choic
new ceo cost associ
product recal mostli account oper
margin return histor rate low
expect firm increas margin increment
basi point thank on-going
remain favor overal revenu growth
profit procedur volum healthcar
util demonstr solid growth sinc
assum stronger growth european region
wake reorgan even though price
pressur ratchet estim stryker
increas revenu annual
think reconstruct segment see growth around
annual hip grow line market
knee outpac market thank mako greater
price pressur larg joint gener complement
stronger growth trauma extrem expect
medical-surg segment grow around led
medic product project neurotech/spin
segment increas annual averag next
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
near term extens tool set use
prepar bone instal implant standard
differ compani long learn curv becom
profici use compani instrument moreov
rel specialist orthoped surgeon skill
experi play outsiz role clinic
outcom patient factor leav surgeon
reluct train master multipl instrument
system especi procedur volum low
maintain high surgic facil one system
surgeon prefer certain vendor stretch back
day resid train research found
surgeon stick prefer vendor sale rep
year use vendor approxim
orthoped procedur time switch
anoth instrument system would requir take
time train develop relationship new
sale rep work less effici earli period
master anoth vendor tool possibl rais risk
patient reduc number procedur
incom surgeon dynam explain market
share among four top orthoped implant maker
remain remark steadi past decad
market share knee implant hover around
zimmer biomet depuy also held share
respect common avenu
signific share gain acquisit
rep provid valuabl servic small group
high-volum surgeon may perform five knee
replac day less need train
sale rep surgeon may wish hire nurs
handl procedur prepar howev
busi quit moati
orthoped firm enjoy sustain advantag
particular intellectu properti keep
new entrant competitor bay firm own
roughli patent around globe act assert
enforc follow chang patent
 switch
first-inventor-to-fil system previous
first-to-inv system think chang favor
moat larger competitor new
system reward compani file time
manner comprehens understand
futur applic technolog deep
pocket oppos newli grant patent rival
end think legal chang translat
challeng patent firm like support
larg legal team better posit take
advantag new law convers new law erect
hurdl keep emerg upstart firm becom
seriou threat peer
relationship sale rep surgeon
intang asset contribut firm sustain
competit advantag
medic devic equip orthoped sale rep play
critic role surgeon sale rep present
everi procedur teach surgeon use tool
kit prepar select instrument
right size sequenc procedur
orthoped surgeon may perform hip
replac knee replac year sale
still believ moat trend stabl mainli owe
chang competit condit orthoped
implant market zimmer acquir smaller rival
biomet consolid orthoped implant
maker take one midtier competitor pictur
make like hospit want
purchas three top-tier manufactur
zimmer biomet account three fourth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
train orthoped surgeon pool even orthoped
surgeon longer enjoy complet autonomi brand
choic switch cost face remain real hospit
need balanc need cost save
consolid vendor challeng accommod
mani surgeon possibl brand choic biomet
acquisit mean fewer hospit need choos
combin top-tier midtier supplier
rais likelihood remain
expect price remain pressur payer
continu whittl away reimburs joint-reconstruct
procedur payment reform would
surpris see medicar cut reimburs
demand expect rise thank first babi boomer
reach key age window knee replac
implant account roughli one third half
procedur reimburs medicar
find much difficult justifi price increas
reimburs remain pressur erod reimburs
also mean orthoped procedur
histor profit center hospit less
profit also suggest orthoped surgeon
less influenc hospit institut shift
cardiovascular neurosurgeri outsiz profit
contribut fortun think foray
neurovascular market establish presenc
medical-surg equip help navig
provid shift
longer term think one
orthoped implant maker emerg intact
period hospit payer belt-tighten hospit
winnow vendor list midtier competitor find
difficult secur hospit contract larger
rival benefit less competit suspect
larg joint-reconstruct market consolid
evolv look much like cardiac rhythm manag
market three major manufactur control
estim market period flirt
possibl acquir smaller competitor smith
industri dynam vendor
consolid put pressur smaller firm
would surpris purchas sooner
rather later
histor leverag close relationship
surgeon get oper room think
posit strategi remain viabl medium term
surgeon could typic freelanc hospit
choic long orthoped surgeon brought
profit procedur hospit hospit will
defer orthoped procedur
profit hospit
manag profit hospit
administr assert bring cost
includ implant control
howev orthoped surgeon reluct go along
chang establish surgeon often activ
resist chang think weaken surgeon
influenc autonomi take place gradual
long time frame unlik primary-car practition
cardiologist repres highest proport
specialist sign hospit healthcar
system employe orthoped surgeon repres last
holdout privat practic current approxim
orthoped surgeon salari hospit system
nearli two third still privat practic
long haul proport employe orthoped
surgeon undoubtedli grow gener
chang consid current rate convers
take year orthoped surgeon reach
level hospit employ cardiologist
alreadi reach meantim orthoped surgeon
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
remain highli independ enjoy autonomi
increas incom fee-for-servic framework resist
hospit effort limit brand choic mani
attempt hospit made rein
analysi team formulari model -- mostli fail
far hospit consolid vendor take advantag
attract volum price success
approach think chanc
secur hospit contract enhanc
biomet part zimmer
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oth acquisit trauson extend
presenc china provid solid foothold
fast-grow chines valu segment orthoped
firm vulner on-going cost relat treat
patient
hospit healthcar system aim
consolid supplier benefit
custom like stick wide
use brand accommod surgeon
oth abil mako robot significantli improv
outcom total knee replac remain
clinic data demonstr
superior mako sale could fall quickli
oconsid resist orthoped surgeon
hospit effort restrict brand choic slow
transit hospit employ think surgeon
influenc wane slowli
oth addit physio-control unlik goos
growth opinion
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
continu enjoy extens financi flexibl
even issu debt financ purchas
larger acquisit worri stryker
pursu state plan continu acquisit
return cash sharehold dividend share
repurchas end septemb firm held net
debt posit billion reflect purchas
product physio-control novadaq entellu
estim debt/ebitda roughli time interest
coverag time year major debt matur
next five year includ million
million believ firm abl
handl matur exist cash intern
rate uncertainti medium reflect
wide diversifi product line-up categori
rel insul macroeconom condit like
medic devic compani expos
product failur recal result hefti legal
fee inventori write-off new emphasi
large-scal devic registri orthoped compani may
find field recal data gather
probabl surfac product problem earlier
current mechan also subject
depart justic investig past
market practic consid symbiot relationship
orthoped devic maker orthoped
surgeon could happen despit legisl
shone stronger light financi transact
manufactur surgeon sever econom condit
new realiti cost-shar increas
vulner larger trend consum spend
long term think gradual shift toward
orthoped surgeon hospit employe linchpin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
moat orthoped may need
entertain altern model sell orthoped implant
especi smith nephew syncera low-touch sale
model success
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
american fund growth fund amer
fidel manag research compani
capit research manag compani
share
fund
share
fund
rate stewardship standard kevin lobo
step presid ceo role fall
lobo lead orthovita join
firm purchas orthovita bulk
orthobiolog offer lobo previou experi
includ time johnson johnson mcneil divis
ethicon contribut deep knowledg
healthcar market med-tech moreov bring
intern experi time canada europ
glenn boehnlein took cfo william jellison
retir strongli indic intend
expand reach faster-grow emerg market
think manag team equip make
major push area expect much chang
strateg prioriti point lobo
underscor firm interest activ
anticip solidifi neurotechnolog
med-surg portfolio intrigu purchas
mako could put influenti posit
steer applic robot surgeri joint replac
would surpris manag acquir
smith nephew next coupl year
latter sport medicin arthroscopi wound-car
busi would fit well portfolio
investor awar littl influenc may
still strong tie found
famili even though board member
consid independ would underestim
sway famili board seat vote power
well sever long-stand board member
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
deliv anoth stellar quarter thank mako
neurotechnolog rais fve oct
stryker third-quart result demonstr well
firm meld smart strategi top-notch
execut year-to-d perform
consist track along expect
alter underli assumpt modestli
rais fair valu estim reflect cash flow realiz
sinc last updat continu fan stryker
wide moat though share consist trade
intrins valu past two half year
weve seen nine quarter grown
knee implant faster market primarili fuel
mako robot third quarter saw knee
rise johnson johnson knee fell
continu steadili place robot train
surgeon firm shi instal
robot notabl util rate grown year
year perhap intrigu hint one
publish prospect studi suggest compar
significantli decreas pain faster recoveri earli
discharg hospit anoth studi found mako
knee patient typic cost approxim less
treat less like use skill nurs follow
surgeri readmiss one third lower
non-mako patient preliminari indic
leav us optimist clinic econom
benefit mako favor data share
major orthoped confer march plan revisit
assumpt long-term mako placement
also continu see strength neurotechnolog
segment firm abl benefit
beefed-up product portfolio coil cathet well
grow adopt stent retriev ischem stroke
expect see low double-digit growth
final think stryker plan acquisit
savvi decis whole fan spine
market domin cater primari
patient degen spinal condit weve long
held clinic underpin mani commonli
perform spinal procedur shaki best
high-qual random control prospect
studi compar outcom procedur
studi exist suggest conserv
measur physic therapi may work well
invas spinal surgeri
howev squar aim complic spinal
market primarili compos moder sever
scoliosi patient pediatr adolesc adult
spine trauma mix clinic valu surgic
treatment type patient clear
significantli higher seen among
degen spinal patient thank foundat
clinic benefit reimburs well-establish
point addit immateri
financi standpoint howev view acquisit
anoth exampl manag team acut
discern
post anoth strong quarter chang
stryker second-quart perform larg met
expect firm remain track hit full-
year project minor adjust model
retain fair valu estim consist
rare see medic technolog
deliv anoth quarter strong growth across three
segment translat consolid
organ growth year year stryker
come
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
perform past two year underscor wide
econom moat especi intang asset includ
on-going innov relationship practition
bolster placement mako robot
seen eight consecut quarter above-market growth
knee perspect second quarter hip
knee grew respect johnson
 johnson hip grew knee declin
anticip strength last least
rival zimmer biomet expect launch
robot total knee replac indic
howev zimmer biomet wrestl
signific oper regulatori challeng
yet fulli quell zimmer biomet make
progress put hous order second half
year think could put littl competit pressur
robot placement
meantim eagerli await clinic data
stryker robot weve discuss previous remain
unclear whether mako robot orthoped robot
matter improv clinic outcom expect
see first hint issu next spring data
mako releas result favor
add fuel robot fire howev neg result
could damp demand robot
on-going scrambl medic technolog competitor
expand product portfolio effort build stronger
relationship hospit custom rumor
angl acquisit
hear confirm negoti price
hold steadi fair valu estim
compani howev base multipl abbott
lab paid st jude medic consid
fair price even though st jude share under-valued
time surmis potenti tie-up stryker
boston could fall close billion
strateg perspect think combin
boston make great deal sens hospit
becom ever consciou reimburs
reform emphas valueinclud patient
outcom cost inputsov volum procedur
two compani extrem complimentari portfolio
orthoped busi capit equip
match neatli boston cardiac franchis
focu consum product even gastroenterolog
two compani overlap presenc
offer strength imag equip boston
focu consum balloon cathet clip
use endoscop procedur
particular like potenti combin would
allow access faster-grow area
cardiovascular structur heart neuromodul
discuss larg joint reconstruct
market face increas price eros becom
difficult introduc meaning innov especi
matur market like hip gener target
cardiac market pool undertr patient
also typic easier conduct clinic trial
demonstr valu innov compar
recogn acquisit boston would
largest transform purchas ever
made combin two compani would give
rise entiti could challeng med-tech
behemoth right although
consist grown tuck-in acquisit
specul manag may understand
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
appreci rival virtu breadth
depth offer hospit pioneer way
partner hospit value-bas reimburs
asid strateg valu combin
remain wari price will pay boston
well integr risk former
histor taken fairli disciplin approach price paid
acquisit moreov follow purchas
medic physio-control debt-to-ebitda
rose sinc paid debt brought
ratio time
regard latter impress stryker
abil acquir long-neglect neurovascular busi
boston scientif turn highli
competit challeng neurovascular
presenc final think boston ceo mike mahoney
clean boston oper last three year
risk take pandora box
dysfunct low
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
